aging, neurologic changes that
occur with 1:220–221, 221–223,
261 ,268–269, 272 , 273 , 275–276,
288–289
aging, nutrition and dietary changes
that occur with 4:176–177, 186 ,
194
aging, otolaryngologic changes that
occur with 1: 7 , 8–9,45–46,
52–54
aging, pulmonary changes that
occur with 2:181–183
aging, reproductive and sexual
changes that occur with
3:242–243
andropause 3:244–245
BPH 3: 248
erection 3: 278
fertility 3: 283
infertility 3: 295
ovarian cancer 3: 312
prostate cancer 3:327–328
prostate gland 3: 330
prostate health 3: 331
PSA 3: 333
puberty 3: 335
vagina 3: 353
aging, urinary system changes that
occur with 3:175–176; 4: 98
aging, vision and eye change that
occur with 1:71–72, 72 t
ARMD 1:70–71
astigmatism 1: 73
bilberry 4: 60
cataract 1:77–78
dacryocystitis 1: 85
dry eye syndrome 1: 86
ectropion 1: 87
glaucoma 1: 94
ischemic optic neuropathy
1:97–98
lutein 4: 79
night blindness 1:102
presbyopia 1:108–109
zeaxanthin 4: 107
AHA. Seealphahydroxyl acid
AIDS. Seeacquired
immunodeficiency syndrome;
HIV/AIDS
AIDS-related Kaposi’s sarcoma
1:168, 169
albinism 1:135–136, 176
albumin 2:124, 127 ,129; 3:73–74,
176, 205, 227
albuminuria 3:176, 177 , 191 , 192 ,
205 , 210 , 211
alcohol 1:313, 362; 2:17, 370;
3:237, 337–338, 384; 4:315–318,
317 t
accidental injuries 4: 5
addiction 4: 314
barbiturates 4: 323
benzodiazepines 4: 324
cancer prevention 4: 14
cannabis 4: 326
cardiovascular disease
prevention 4: 16
chloral hydrate 4: 327
club drugs 4: 328
dependence 4: 330
depressants 4: 332
drugs 4: 145
ethchlorvynol 4: 334
FAS 4:334, 335
flunitrazepam 4: 336
GABA 4: 336
hangover 4: 338
intoxication 4: 341
naltrexone 4: 344
overdose 4: 164
sobriety 4: 350
substance abuse 4: 311
substance abuse treatment 4: 351
water safety 4: 50
withdrawal syndrome 4: 354
alcoholic hallucinosis 4:319
alcoholic hepatitis 3:56, 71
alcohol interactions with
medications 4:318–319
alcoholism 1:262; 3:80, 81, 89,
381, 385; 4:319–320
alcohol 4: 317
alcohol interactions with
medications 4: 318
disulfiram 4: 333
hangover 4: 338
aldosterone 2:80, 256; 3:111–112
Addison’s disease 3: 106
adrenal glands 3:107, 108
endocrine system 3: 99
hyperaldosteronism 3: 136
hyperkalemia 3: 138
renin 3: 158
stress response hormonal
cascade 3: 159
urinary system 3: 171
aldosteronism. See
hyperaldosteronism
alimentary system. See
gastrointestinal system
alkaline phosphatase (ALP) 1:348;
3: 75alkylating agents 2:375, 375t
alkyl nitrites 4:320–321, 320 t
ALL. Seeacute lymphocytic
leukemia
allele 4:113, 113 t, 127 , 135
allergen 2:201, 236, 239–240, 240 t,
243, 258, 260
allergic asthma 2: 190 , 240,247,
258, 269, 280
allergic conjunctivitis 2:240–241,
258
allergic dermatitis 2:241–242
allergic reaction. See
hypersensitivity reaction
allergic rhinitis 1:8, 51; 2:188, 240,
241 , 242–243,258, 288
allergy 1:18, 150, 368; 2:120, 236,
243–244,258, 298; 4:152, 381,- See alsohypersensitivity
reaction; immune system and
allergies
allergy testing 2: 241 , 244, 258
alopecia 1: 135 , 136–138, 137 t,162,
173
alopecia areata 1: 137 , 138
alpha adrenergic antagonists. See
alpha blockers
alpha blockers 2:77–78, 78t, 84 t
alpha fetoprotein (AFP) 3:243, 244 ,
263 ,345; 4:12, 130
alphahydroxyl acid (AHA) 1:144,
171
alpha-1-antitrypsin (AAT)
deficiency 2:200, 216
Alport’s syndrome 3:176–177,
208
alternative and complementary
approaches to conventional
medicine 4:51–55, 51–108, 57 ,
81 , 84 , 93
alternative and complementary
remedies for cancer 2:367–368
alternative methods for pain relief
1:365–366, 380
altitude sickness 2:205, 216, 217
alveolus 2:183
berylliosis 2: 192
bronchoscopy 2: 197
bronchus 2: 198
COPD 2: 199
lungs 2: 212
oxygen-carbon dioxide
exchange 2: 214
pleura 2: 218
pulmonary edema 2: 223
pulmonary fibrosis 2: 226
Index 445